| 688596 | 正帆科 | 1.63 | 2.40 | 36.45 | 36.83 | 1.05 | | --- | --- | --- | --- | --- | --- | --- | | | 技 | | | | | | | 301428 | 世纪恒 | 1.72 | 5.41 | 40.99 | 41.36 | 0.90 | | | 通 | | | | | | | 300341 | 麦克奥 | 1.02 | 1.57 | 16.74 | 16.88 | 0.86 | | | 迪 | | | | | | | 688366 | 昊海生 | 1.00 | 0.49 | 54.41 | 54.81 | 0.73 | | | 科 | | | | | | | 000801 | 四川九 洲 | 4.85 | 4.78 | 15.90 | 16.01 | 0.72 | | 002899 | 英派斯 | 0.75 | 1.99 | 22.73 | 22.89 | 0.71 | | 601865 | 福莱特 | 0.70 | 0.66 | 17.1 1 | 17.23 | 0.69 | | 6051 1 1 | 新洁 ...

天弘医疗健康混合A基金经理为吕俏。 资料显示，天弘基金管理有限公司成立于2004年11月，董事长为黄辰立，总经理为高阳。目前，天弘基金共有8名股东，蚂蚁科技集团股份有限公司持股 51%、天津信托有限责任公司持股16.80%、内蒙古君正能源化工集团股份有限公司持股15.60%、芜湖高新投资有限公司持股5.60%、新疆天瑞博丰股权投资 合伙企业（有限合伙）持股3.50%、新疆天聚宸兴股权投资合伙企业（有限合伙）持股3.50%、新疆天惠新盟股权投资合伙企业（有限合伙）持股2%、新疆 天阜恒基股权投资合伙企业（有限合伙）持股2%。 7月22日，英派斯连续4个交易日下跌，区间累计跌幅-7.54%。青岛英派斯健康科技股份有限公司是一家专注于全品类、多系列健身器材开发制造与销售、品 牌化运营的知名厂商,致力于为满足消费者多样化的健身需求,提供兼具功能性、智能化与安全性的各式健身器材。 简历显示，吕俏女士:金融学、西方经济学硕士。历任泰康资产管理有限责任公司股票研究经理、淡水泉(北京)投资管理有限公司投资经理,2023年2月加盟天 弘基金管理有限公司。现任天弘基金管理有限公司基金经理助理。2024年6月18日起担任天弘医药创 ...

Core Insights - The successful integration of the "Feitian" series core muscle training device into the Chinese space station marks a historic breakthrough in China's fitness technology within the aerospace sector [1][4] - The device addresses the "three major health challenges" faced by astronauts in a microgravity environment, including fluid redistribution, bone density loss, and cardiovascular issues [2][4] - The company, Yingpais, has evolved from an OEM to a leader in technological innovation in the fitness equipment industry, with a significant increase in revenue and net profit in 2024 [8][10] Company Development - Yingpais has developed the "Feitian" device over nearly two years, featuring a revolutionary design that allows for comprehensive health protection for astronauts [4][6] - The company has established a robust product system covering various fitness categories and has a global sales network, demonstrating its strong market presence [8] - Yingpais has accumulated over 338 patents, including 38 invention patents, showcasing its commitment to technological innovation [8] Strategic Partnerships and Contributions - The company has actively participated in national strategic initiatives, including the development of equipment for the Beijing Winter Olympics and the Chinese space program [10][11] - Yingpais has formed strategic collaborations with academic institutions to develop specialized training equipment for athletes, further enhancing its role in supporting national sports [11] - The company aims to leverage its technological advancements to benefit both elite athletes and the general public, contributing to the broader goal of promoting health in China [13]

Core Insights - The successful launch of the Tianzhou-9 cargo spacecraft carrying the "Feitian" series core muscle training device developed by Qingdao Inspurs Health Technology Co., Ltd. marks a significant achievement in supporting astronauts' health in space [1][2] - The "Feitian" series device is a groundbreaking innovation that addresses the physiological challenges astronauts face in a microgravity environment, enhancing their ability to counteract negative health effects [2] Company Overview - Qingdao Inspurs Health Technology Co., Ltd. has been selected by the China Astronaut Research and Training Center to develop and produce the next-generation comprehensive fitness equipment for astronauts, showcasing its strong research and production capabilities [1] - The company is recognized as a pioneer in China's fitness industry, contributing significantly to the sustainable development of China's manned space program by providing essential health support [2] Industry Impact - The integration of high-end fitness technology with China's space engineering represents a milestone, establishing the "Feitian" series as a core life support equipment for maintaining astronauts' physical and mental health during long-term missions [2] - The successful development of this device not only enhances the capabilities of Chinese astronauts but also lays a solid foundation for future deep space exploration missions [2]

Group 1: Core Business and Innovations - The successful launch of the "Feitian" series core muscle training device by Yingpais (002899) marks a significant milestone in the integration of Chinese aerospace engineering and high-end fitness technology [1][3] - The "Feitian" series device is designed to address the physiological challenges faced by astronauts in a microgravity environment, such as muscle atrophy and bone density loss, which occurs at a rate of 1% per month [3] - Yingpais has established itself as a pioneer in the Chinese fitness industry, focusing on the development, manufacturing, and sales of a wide range of fitness equipment, and aims to create healthier and more efficient fitness solutions for the public [4] Group 2: Financial Performance - According to Yingpais' 2024 annual report, the company achieved a revenue growth of 35.58% year-on-year, with a net profit attributable to shareholders increasing by 23.77% and a non-recurring net profit growth of 24.28% [4] Group 3: Research and Development - Yingpais has a strong research and development foundation, with a team of hundreds and a total of 338 valid patents, including 38 invention patents and 199 utility model patents [6] - The company has transitioned from providing OEM services for international brands to mastering core technologies in structural design, product assembly, process innovation, and quality testing [5]

Investment Rating - The investment rating for the company is "Buy-A" with a target price of 27.02 CNY, indicating a potential upside from the current price of 23.30 CNY [3][10][12]. Core Insights - The company is entering the AI glasses market through a strategic partnership with Li Weike, aiming to create a new growth curve by developing smart sports equipment tailored for vertical scenarios like cycling and fitness [1][2]. - The AI glasses market shows significant growth potential, with global shipments expected to reach 12.05 million units by 2025, representing an 18.3% year-on-year increase [2]. - The company has established a comprehensive sales network across 34 provincial-level administrative regions in China, focusing on both commercial and home fitness equipment [3][6]. - The company has successfully penetrated international markets with its IMPULSE brand and is also engaged in OEM/ODM production for well-known fitness brands [3][6]. Financial Performance - For the fiscal year ending December 31, 2024, the company reported revenues of 1.214 billion CNY, with a year-on-year growth of 35.58% [7][8]. - The company expects revenues to grow to 1.325 billion CNY in 2025, with a projected year-on-year increase of 9.16% [8][12]. - The net profit for 2025 is estimated to be 114 million CNY, reflecting a growth of 4.57% compared to the previous year [8][12]. Market Position and Strategy - The company is positioned as a leading player in the domestic fitness equipment industry, leveraging its strengths in product development and market reach to capitalize on emerging trends in smart fitness technology [2][10]. - The partnership with Li Weike is expected to enhance the company's capabilities in the consumer-grade AI hardware market, creating synergies through a "hardware + service" business model [2][10]. - The company aims to maintain a stable growth trajectory in its commercial product segment, with expected revenue growth rates of 7.16% to 15.09% from 2025 to 2027 [9][12].

Investment Rating - The report maintains a positive outlook on the smart glasses industry, indicating a robust growth trajectory and recommending attention to key players such as 康耐特光学, 明月镜片, 博士眼镜, and 英派斯 [5][31]. Core Insights - The smart glasses market is experiencing rapid growth, driven by the introduction of AI and AR glasses, with significant potential for long-term expansion [2][6]. - The industry is at a pivotal point where traditional eyewear is evolving, and midstream lens manufacturing and downstream eyewear channels remain crucial [3][7]. - The report highlights the increasing integration of advanced functionalities in smart glasses, which enhances user interaction and expands application scenarios [18][19]. Summary by Sections 1. Smart Glasses: AI and AR Glasses Flourishing - AI glasses, exemplified by Meta's RayBan Meta, have ignited market interest, with significant sales growth expected [24][29]. - AR glasses are evolving with continuous optical solution iterations, broadening their application scope [6][18]. - The market is witnessing a surge in domestic players, with companies like 雷鸟创新, Xreal, and Rokid rapidly developing their product lines [4][6]. 2. Transformation of Traditional Eyewear - The midstream lens manufacturing sector is seeing steady global demand growth, with a shift towards higher-value, functional products [4][7]. - Downstream channels, particularly offline retail, play a vital role in capturing consumer trends and facilitating product development [9][7]. - The report emphasizes the importance of collaboration between smart glasses manufacturers and established eyewear retailers to enhance market penetration [9][7]. 3. Key Companies to Watch - 康耐特光学 is positioned as a leading lens manufacturer, focusing on domestic market growth and XR business opportunities [5][31]. - 明月镜片 is enhancing its product structure and actively engaging in high-growth segments like AI glasses [5][31]. - 博士眼镜 is expanding its retail presence and integrating smart glasses into its service offerings [5][31]. - 英派斯 is diversifying into the AI glasses sector while maintaining steady growth in its core fitness equipment business [5][31].

Core Viewpoint - The AI glasses concept has seen a significant surge, with companies like Zhili Fang experiencing over a 10% increase in stock price following the announcement of Xiaomi's AI glasses launch [1] Group 1: Market Reaction - Zhili Fang's stock rose by more than 10% during the trading session [1] - Other companies in the sector, including Hao Shang Hao, Pinming Technology, and others, also saw their stock prices increase [1] Group 2: Product Launch - Xiaomi officially announced that it will unveil its "next-generation personal smart device," which is the Xiaomi AI glasses, on the evening of June 26 [1] - Rokid Glasses, the world's first mass-produced consumer-grade AI+AR glasses, officially began mass production on June 24, with 250,000 global pre-orders already secured [1] - The Rokid product has achieved a breakthrough in domestic production across the entire supply chain [1]

Group 1 - The A-share football concept stocks experienced a decline at the beginning of trading [1] - Kangliyuan hit the daily limit down [1] - Jinling Sports fell over 8% [1] - Xinghui Entertainment dropped over 5% [1] - Other companies such as Palm Holdings, Yingpais, and Tanuo also saw declines [1]

Core Viewpoint - Qingdao Inpace Health Technology Co., Ltd. has announced its 2024 annual profit distribution plan, which includes a cash dividend of 0.75 yuan per 10 shares for all shareholders, based on a total share capital of 146,540,276 shares after excluding repurchased shares [2][3][6]. Summary by Sections Dividend Distribution Plan - The company will distribute a cash dividend of 0.75 yuan per 10 shares (including tax), totaling 10,990,520.70 yuan (including tax) [2][6]. - The cash dividend per share is calculated as 0.0743622 yuan, derived from the total cash dividend divided by the total share capital [3][10]. Share Capital and Repurchase Impact - The total share capital before and after the dividend distribution remains unchanged, despite the repurchase of 1,256,700 shares, which do not participate in the dividend distribution [4][10]. - The dividend distribution will be based on the adjusted total share capital of 146,540,276 shares [2][6]. Key Dates - The record date for the dividend distribution is set for June 11, 2025, and the ex-dividend date is June 12, 2025 [6][7]. Dividend Payment Method - Cash dividends will be directly credited to the accounts of A-share shareholders through their respective securities companies on the ex-dividend date [8]. - The company will handle the distribution of cash dividends for certain A-share shareholders who may have insufficient dividends due to account share reductions during the application period [9]. Taxation Details - The company will not withhold individual income tax for certain shareholders, with tax obligations calculated based on the holding period of the shares [6][10].